WilmerHale Advises Embark Veterinary in $75M Series B Funding
On July 26, 2021, Embark Veterinary, Inc., the top rated provider of dog DNA tests, announced that it secured $75 million in a Series B funding round led by SoftBank, with additional investors including F-Prime Capital, Slow Ventures, Freestyle Capital and Third Kind Venture Capital. Embark’s DNA-based analytics seeks to curb preventable diseases and increase the lifespan of dogs. The funding will be used to expand hiring and accelerate the development of Embark’s robust discovery engine.
The team representing Embark consisted of David A. Westenberg, Jon Jones, J.P. Mohler, and Cindy Sullivan.